Global Mononucleosis Diagnostic Market Size (2024 - 2029)

The mononucleosis diagnostics market is anticipated to experience growth over the forecast period, driven by increased health awareness, technological advancements, and a rising adolescent population. The COVID-19 pandemic significantly influenced the market, as it heightened the focus on infectious disease management, particularly related to Epstein-Barr virus infections. This led to a surge in demand for diagnostics during and after the pandemic. Despite the market's stabilization post-COVID-19, the limited availability of diagnostic tests remains a challenge to faster market expansion.

Market Size of Global Mononucleosis Diagnostic Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Mononucleosis Diagnostic Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 4.80 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Mononucleosis Diagnostic Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Mononucleosis Diagnostic Market Analysis

During the time frame of the forecast, the mononucleosis diagnostics market is expected to grow at a CAGR of nearly 4.8%.

The COVID-19 outbreak substantially impacted the mononucleosis diagnostics market as the pandemic increased the focus on the management of infectious diseases to limit their spread. This was attributed to the fact that COVID-19 was associated with Epstein-Barr virus (EBV) infections. For instance, as per an article published in September 2021 by BMC Infectious Diseases, out of the 128 patients with COVID-19, 13.3% were infected with Epstein-Barr virus reactivation. As per an update published in February 2022 by the University Health Network, long COVID-19 symptoms were also found in active EBV infections, and close to 70% of the COVID patients had reactivated EBV. It went on to say that EBV reactivation could be the cause of long COVID-19. Thus, such studies and updates indicate the demand for diagnosing EBV among the patient population increased during the pandemic. In addition, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased and the disease screening services have been resumed.

The major factors responsible for the growth of the global mononucleosis diagnostics market include rising health awareness and knowledge among patients, technological advancements leading to faster diagnosis, and the rise in the adolescent population. During the next few years, these factors are likely to continue to help the market grow.

Technological advancements leading to faster diagnosis are primarily driving the market's growth. For instance, in April 2021, Roche launched the Elecsys EBV panel, which consists of Elecsys EBV IgM, Elecsys EBV VCA IgG, and Elecsys EBV EBNA IgG immunoassays, in countries accepting the CE Mark. Additionally, in January 2022, Quanterix Corporation reported that its Simoa technology had been proven to be significant in identifying a high prevalence of EBV associated with multiple sclerosis (MS). Thus, growing technological advances in the mononucleosis diagnostics market are expected to increase demand over the forecast period.

Moreover, as per the study published in August 2022 by Frontiers in Immunology, within 10 years from the index date, the incidence of MS was 22.6 cases per 100,000 person-years among patients with infectious mononucleosis but only 11.9 cases per 100,000 person-years among individuals without infectious mononucleosis. So, the growing number of cases of mononucleosis is likely to help the study market grow over the next few years.

Still, the fact that there aren't many tests for diagnosing mononucleosis is a big reason why the market isn't growing faster.

Mononucleosis Diagnostic Industry Segmentation

As per the scope of the report, infectious mononucleosis, also called "mono," is a contagious disease. Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis, but other viruses can also cause this disease. It is common among teenagers and young adults, especially college students. Mononucleosis diagnostics refers to the detection of the Epstein-Barr virus (EBV). The market comprises various detection tests used for the diagnosis of mononucleosis. There are various tests available on the market, such as the monospot test, complete blood count test, and Epstein-Barr virus (EBV) antibody test. The mononucleosis diagnostics market is segmented by type of test (monospot test, complete blood count test, and Epstein-Barr virus (EBV) antibody test), end user (hospitals, laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, the Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report provides value in USD million for the aforementioned segments.

By Type of Test
Monospot Test
Complete Blood Count Test
Epstein Barr Virus (EBV) Antibody Test
By End-User
Hospitals
Laboratories
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Mononucleosis Diagnostic Market Size Summary

The mononucleosis diagnostics market is poised for steady growth, driven by increasing health awareness, technological advancements, and a rising adolescent population. The market experienced a significant impact due to the COVID-19 pandemic, which heightened the focus on infectious disease management, particularly related to Epstein-Barr virus (EBV) infections. This led to an increased demand for EBV diagnostics, as studies linked COVID-19 with EBV reactivation. As global restrictions eased, the market began stabilizing, with resumed disease screening services. Technological innovations, such as Roche's Elecsys EBV panel and Quanterix Corporation's Simoa technology, are expected to further propel market growth by enabling faster and more accurate diagnoses. Despite the limited number of diagnostic tests available, the monospot test is anticipated to dominate the market segment due to its high sensitivity and specificity, along with its cost-effectiveness and rapid antibody detection capabilities.

The Asia-Pacific region is projected to experience the highest growth rate in the mononucleosis diagnostics market, driven by a substantial adolescent population susceptible to EBV infections. The region's demographic trends, coupled with the presence of key industry players like Cardinal Health and Abbott, present significant market opportunities. The high prevalence of EBV and its association with mononucleosis, particularly among teenagers, underscores the demand for diagnostic tests. Major companies in the market are focusing on developing advanced products to enhance detection speed and accuracy. Recent innovations, such as Eurofins Viracor's T Cell test and Hologic's molecular assays, highlight the ongoing efforts to improve diagnostic capabilities, further supporting market expansion over the forecast period.

Explore More

Global Mononucleosis Diagnostic Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Health Awareness and Knowledge among Patients

      2. 1.2.2 Rise in Prevalence of Mononucleosis

    3. 1.3 Market Restraints

      1. 1.3.1 Limitations of Available Tests for the Diagnosis of Mononucleosis

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Type of Test

      1. 2.1.1 Monospot Test

      2. 2.1.2 Complete Blood Count Test

      3. 2.1.3 Epstein Barr Virus (EBV) Antibody Test

    2. 2.2 By End-User

      1. 2.2.1 Hospitals

      2. 2.2.2 Laboratories

      3. 2.2.3 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Mononucleosis Diagnostic Market Size FAQs

The Global Mononucleosis Diagnostic Market is projected to register a CAGR of 4.80% during the forecast period (2024-2029)

Abbott Laboratories, Thermo Fischer Scientific Inc., Danaher Corporation, Cardinal Health Inc. and Bio Rad Laboratories Inc. are the major companies operating in the Global Mononucleosis Diagnostic Market.

Mononucleosis Diagnostic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)